These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 22802682

  • 1. Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.
    Meng Y, Liu S, Li J, Meng Y, Zhao X.
    Int J Nanomedicine; 2012; 7():3133-42. PubMed ID: 22802682
    [Abstract] [Full Text] [Related]

  • 2. Mono-PEGylation of Alpha-MMC and MAP30 from Momordica charantia L.: Production, Identification and Anti-Tumor Activity.
    Sun Y, Sun F, Li J, Wu M, Fan X, Meng Y, Meng Y.
    Molecules; 2016 Oct 31; 21(11):. PubMed ID: 27809255
    [Abstract] [Full Text] [Related]

  • 3. A novel method for simultaneous production of two ribosome-inactivating proteins, α-MMC and MAP30, from Momordica charantia L.
    Meng Y, Lin S, Liu S, Fan X, Li G, Meng Y.
    PLoS One; 2014 Oct 31; 9(7):e101998. PubMed ID: 25003606
    [Abstract] [Full Text] [Related]

  • 4. PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of α-momorcharin in vivo.
    Zheng JC, Lei N, He QC, Hu W, Jin JG, Meng Y, Deng NH, Meng YF, Zhang CJ, Shen FB.
    Immunopharmacol Immunotoxicol; 2012 Oct 31; 34(5):866-73. PubMed ID: 22439816
    [Abstract] [Full Text] [Related]

  • 5. PEGylation of alpha-momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potential.
    Bian X, Shen F, Chen Y, Wang B, Deng M, Meng Y.
    Biotechnol Lett; 2010 Jul 31; 32(7):883-90. PubMed ID: 20238144
    [Abstract] [Full Text] [Related]

  • 6. Α-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells.
    Fan X, He L, Meng Y, Li G, Li L, Meng Y.
    Mol Med Rep; 2015 May 31; 11(5):3553-8. PubMed ID: 25573293
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol.
    Li M, Chen Y, Liu Z, Shen F, Bian X, Meng Y.
    Acta Biochim Biophys Sin (Shanghai); 2009 Sep 31; 41(9):792-9. PubMed ID: 19727528
    [Abstract] [Full Text] [Related]

  • 8. Immunoaffinity purification of α-momorcharin from bitter melon seeds (Momordica charantia).
    Yao X, Li J, Deng N, Wang S, Meng Y, Shen F.
    J Sep Sci; 2011 Nov 31; 34(21):3092-8. PubMed ID: 21994203
    [Abstract] [Full Text] [Related]

  • 9. Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy.
    Puri M, Kaur I, Kanwar RK, Gupta RC, Chauhan A, Kanwar JR.
    Curr Mol Med; 2009 Dec 31; 9(9):1080-94. PubMed ID: 19747115
    [Abstract] [Full Text] [Related]

  • 10. Ribosome-inactivating Protein MAP30 Isolated from Momordica Charantia L. Induces Apoptosis in Hepatocellular Carcinoma Cells.
    Zhou Y, Yang D, Qiang Z, Meng Y, Li R, Fan X, Zhao W, Meng Y.
    Recent Pat Anticancer Drug Discov; 2024 Dec 31; 19(2):223-232. PubMed ID: 36330636
    [Abstract] [Full Text] [Related]

  • 11. Ribosome-Inactivating Protein α-Momorcharin Derived from Edible Plant Momordica charantia Induces Inflammatory Responses by Activating the NF-kappaB and JNK Pathways.
    Chen YJ, Zhu JQ, Fu XQ, Su T, Li T, Guo H, Zhu PL, Lee SK, Yu H, Tse AK, Yu ZL.
    Toxins (Basel); 2019 Nov 26; 11(12):. PubMed ID: 31779275
    [Abstract] [Full Text] [Related]

  • 12. Alpha-momorcharin possessing high immunogenicity, immunotoxicity and hepatotoxicity in SD rats.
    Meng Y, Liu B, Lei N, Zheng J, He Q, Li D, Zhao X, Shen F.
    J Ethnopharmacol; 2012 Jan 31; 139(2):590-8. PubMed ID: 22172326
    [Abstract] [Full Text] [Related]

  • 13. PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo.
    Deng NH, Wang L, He QC, Zheng JC, Meng Y, Meng YF, Zhang CJ, Shen FB.
    Drug Deliv; 2016 Jan 31; 23(1):95-100. PubMed ID: 24786488
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity.
    Chen WW, Zhang HR, Huang ZG, Zhou ZY, Lou QW, Jiang XY, Zhu ZH.
    Protein Expr Purif; 2021 Sep 31; 185():105893. PubMed ID: 33933613
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MAP30 and luffin-α: Novel ribosome-inactivating proteins induce plant systemic resistance against plant viruses.
    Wei Z, Yang L, Liu W, Xu X, Ran M, Jin Y, Sun X.
    Pestic Biochem Physiol; 2023 Apr 31; 191():105342. PubMed ID: 36963924
    [Abstract] [Full Text] [Related]

  • 18. Recombinant expression and purification of a MAP30-cell penetrating peptide fusion protein with higher anti-tumor bioactivity.
    Lv Q, Yang XZ, Fu LY, Lu YT, Lu YH, Zhao J, Wang FJ.
    Protein Expr Purif; 2015 Jul 31; 111():9-17. PubMed ID: 25797209
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Expression of recombinant ribosome inactivating protein MAP30 in E.coli and its biological activity].
    Zhang LL, Ding Q, Zhan JB.
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 May 31; 39(3):264-71. PubMed ID: 20544988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.